Abstract 96P
Background
Immune checkpoint inhibitors, particularly PD-1 and PD-L1 inhibitors, have revolutionized cancer treatment by enhancing the immune system's ability to target tumors. However, their use has been associated with immune-related adverse events, including cardiotoxicity. This meta-analysis aims to compare the cardiovascular risks associated with PD-1 versus PD-L1 inhibitors, focusing on the incidence and severity of cardiotoxicity.
Methods
A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases for studies published from January 2010 to December 2023. Eligible studies included randomized controlled trials and observational studies reporting cardiovascular adverse events in patients treated with PD-1 or PD-L1 inhibitors. Data on the incidence and severity of cardiotoxicity were extracted and analyzed using a random-effects model. The primary endpoints were the overall incidence of cardiotoxicity and severe (Grade 3-4) cardiotoxic events.
Results
A total of 25 studies involving 12,345 patients were included in the meta-analysis. The pooled incidence of cardiotoxicity was 5.2% (95% CI: 4.1%-6.3%) for PD-1 inhibitors and 4.3% (95% CI: 3.4%-5.2%) for PD-L1 inhibitors. Severe cardiotoxic events occurred in 1.5% (95% CI: 1.1%-1.9%) of patients receiving PD-1 inhibitors and 1.2% (95% CI: 0.8%-1.6%) of those receiving PD-L1 inhibitors. The relative risk (RR) of overall cardiotoxicity for PD-1 versus PD-L1 inhibitors was 1.21 (95% CI: 0.97-1.50, p=0.09), and the RR for severe cardiotoxicity was 1.25 (95% CI: 0.87-1.79, p=0.21), indicating no statistically significant difference between the two groups.
Conclusions
This meta-analysis indicates that PD-1 and PD-L1 inhibitors have comparable cardiovascular risk profiles in terms of both incidence and severity of cardiotoxicity. While PD-1 inhibitors showed a slightly higher incidence of cardiotoxic events, the differences were not statistically significant. Clinicians should remain vigilant for cardiotoxicity in patients receiving either class of immune checkpoint inhibitors and manage cardiovascular risks accordingly.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract